Frovatriptan is Effective and Well Tolerated in Korean Migraineurs: A Double-Blind, Randomized, Placebo-Controlled Trial

다국어 초록 (Multilingual Abstract)

Background and Purpose Frovatriptan is a selective 5-HT1B/1D agonist with a long duration of action and a low incidence of side effects. Although several placebo-controlled trials have documented the clinical efficacy and safety of frovatriptan in adults with migraine, this drug has not previously been studied in Asian including Korean patients.
Methods In this double-blind multicenter trial, 229 patients with migraine were randomized to receive frovatriptan 2.5 mg or placebo upon the occurrence of a moderate-to-severe migraine.
The primary outcome was the 2-hour headache response rate.
Results Frovatriptan significantly increased the 2-hour headache response rate compared with placebo (52.9% vs. 34.0%, p=0.004). The headache response rates at 4, 6, and 12 hours were significantly higher in the frovatriptan group than in the placebo group, as was the pain-free rate at 2hours (19.0% vs. 5.7%, p=0.004), 4 hours (40.7% vs. 23.0%, p=0.006), and 6 hours (56.1% vs. 34.0%,p=0.002). The median time to a headache response was significantly shorter in the frovatriptan group than in the placebo group (2.00 hours vs. 3.50 hours, p<0.001). The use of rescue medications was more common in the placebo group (p=0.005). Chest tightness associated with triptan was infrequent (2.5%), mild, and transient.
Conclusions These results demonstrate that 2.5-mg frovatriptan is effective and well tolerated in Korean migraineurs for acute treatment of migraine attacks.

참고문헌 (Reference)

1 Sakai F, "Zolmitriptan is effective and well tolerated in Japanese patients with migraine:a dose-response study" 22 : 376-383, 2002

2 Tfelt-Hansen P, "Triptans in migraine:a comparative review of pharmacology,pharmacokinetics and efficacy" 60 : 1259-1287, 2000

3 Yates RA, "The pharmacokinetics of the antimigraine compound zolmitriptan in Japanese and Caucasian subjects" 58 : 247-252, 2002

4 강나미, "Screening of the A11084G Polymorphism and Scanning of a Mitochondrial Genome SNP in Korean Migraineurs" 대한신경과학회 3 (3): 127-132, 2007

5 Dahlof C, "Safety and tolerability of the novel 5-HT 1B/1D agonist rizatriptan in migraineurs" (Suppl 1) : S16-S18, 1999

6 Brown AM, "SB 209509 (VML 251), a potent constrictor of rabbit basilar artery with high affinity and selectivity for human 5-HT1D receptors" 119 : 110P-, 1996

7 Ferrari MD, "Oral triptans(serotonin 5-HT(1B/1D)agonists)in acute migraine treatment:a meta-analysis of 53 trials" 358 : 1668-1675, 2001

8 Jo KD, "Oral sumatriptan for acute treatment of migraine A single-blind placebo-controlled study" 13 : 77-83, 1995

9 Rapoport AM, "Optimizing the dose of zolmitriptan(Zomig,311C 90)for the acute treatment of migraine.A multicenter,double-blind,placebo-controlled,dose range-finding study.The 017 Clinical Trial Study Group" 49 : 1210-1218, 1997

10 Ferrari MD, "On serotonin and migraine:a clinical and pharmacological review" 13 : 151-165, 1993

11 Wang SJ, "Intranasal sumatriptan study with high placebo response in Taiwanese patients with migraine" 70 : 39-46, 2007

12 "Headache Classification Committee of the International Headache Society.The International Classification of Headache Disorders,2nd edition" 1 : 1-160, 2004

13 Goldstein J, "Frovatriptan for the acute treatment of migraine:a dose-finding study" 42 : 41-48, 2002

14 Sakai F, "Eletriptan for the acute treatment of migraine:results of bridging a Japanese study to Western clinical trials" 20 : 269-277, 2004

15 Havanka H, "Efficacy of naratriptan tablets in the acute treatment of migraine:a dose-ranging study.Naratriptan S2WB2004 Study Group" 22 : 970-980, 2000

16 Pfaffenrath V, "Efficacy and safety of sumatriptan tablets (25 mg, 50 mg, and 100 mg) in the acute treatment of migraine: defining the optimum doses of oral sumatriptan" 38 : 184-190, 1998

17 Lee SB, "Double-blind placebo-controlled randomized clinical trial of zolmitriptan in acute treatment of migraine" 19 : 29-35, 2001

18 Rapoport A, "Dose range-finding studies with frovatriptan in the acute treatment of migraine" 42 : S74-S83, 2002

19 Shimazawa R, "Development of triptans in Japan:bridging strategy based on the ICH-E5 guideline" 52 : 443-449, 2006

20 Ryan R, "Clinical efficacy of frovatriptan: placebo-controlled studies" 42 (42): S84-S92, 2002

21 Silberstein SD, "A randomized trial of frovatriptan for the intermittent prevention of menstrual migraine" 63 : 261-269, 2004

22 Noh YW, "A double-blinded,placebo-controlled,multicenter cross-over study of 2.5mg naratriptan in acute migraineurs" 2 : 53-60, 2001

23 Protocol No, "251/96/07 Clinical Study Report"